BRAF and neoplasm: ABMs can thus be used to simulate how drug-resistant tumour subclones (e.g. melanoma cells with elevated BRAF levels) and drug-sensitive tumour subclones evolve in time and space in response to various drug combinations, drug doses and drug treatment schedules.